Pegfilgrastim

Pegfilgrastim
Clinical data
Trade names	originally Neulasta, other brand names worldwide
AHFS/Drugs.com	Monograph
MedlinePlus	a607058
License data	EU EMA: by INN;
ATC code	L03AA13 (WHO) ;
Legal status
Legal status	US: ℞-only;
Pharmacokinetic data
Elimination half-life	15–80 hrs
Identifiers
	IUPAC name N-(3-Hydroxypropyl)Methionylcolony-stimulating Factor (human), 1-Ether with .Alpha.-Methyl-.Omega.-Hydroxypoly(Oxyethylene);
CAS Number	208265-92-3 ;
IUPHAR/BPS	6969;
DrugBank	DB00019 ;
ChemSpider	none;
UNII	3A58010674;
KEGG	D06889 ;
ChEMBL	ChEMBL1201568 ;
ECHA InfoCard	100.169.155
Chemical and physical data
Formula	C845H1343N223O243S9 + PEG
Molar mass	39,000 g/mol g·mol−1
	(what is this?) (verify)

Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (GCSF) analog filgrastim. It serves to stimulate the level of white blood cells (neutrophils).^[2]

Pegfilgrastim treatment can be used to stimulate bone marrow to produce more neutrophils to fight infection in patients undergoing chemotherapy.^[3]

Pegfilgrastim has a human half-life of 15 to 80 hours, much longer than the parent filgrastim (3–4 hours).^[4]^[3]

In the United States as of 2015 the branded form costs between $5,327 and $8,191 a dose.^[5]

As of 9-22-15 a 6 MG/0.6ML dose costs $15,016.29 in the United States.

Biosimilars

In July 2016 the US FDA rejected a biosimilar application from Sandoz.^[6]

In 2016 Coherus BioSciences is running clinical studies on its own pegfilgrastim biosimilar CHS-1701.^[6]

^ Drugs.com International brand names for pegfilgrastim Page accessed April 1, 2016
^ Walsh, G, Spada, S. "Epogen/Procrit" in: Directory of approved biopharmaceutical products. CRC Press, 2005, pp. 136–37.
^ ^a ^b Drugs.com: Pegfilgrastim
^ Ho, R.J.Y., Gibaldi, M. Biotechnology and biopharmaceuticals: transforming proteins and genes into drugs Wiley-IEEE, 2003, pp. 139, 158.
^ Langreth, Robert (June 29, 2016). "Decoding Big Pharma's Secret Drug Pricing Practices". Bloomberg. Retrieved 15 July 2016.
^ ^a ^b US FDA rejects Sandoz’s Neulasta biosimilar. 19 July 2016

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.